Analysts Set Cryoport, Inc. (NASDAQ:CYRX) Price Target at $18.63

Cryoport, Inc. (NASDAQ:CYRX) has earned an average rating of “Hold” from the seven analysts that are presently covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $18.63.

Several research analysts have recently issued reports on the stock. UBS Group increased their price objective on shares of Cryoport from $14.50 to $17.00 and gave the company a “neutral” rating in a report on Friday, March 15th. Needham & Company LLC decreased their price objective on shares of Cryoport from $19.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, March 13th. Jefferies Financial Group assumed coverage on shares of Cryoport in a report on Thursday, April 4th. They issued a “buy” rating and a $21.00 price objective for the company. Finally, Stephens reiterated an “equal weight” rating and issued a $17.00 price objective on shares of Cryoport in a report on Wednesday, March 13th.

Insider Buying and Selling

In related news, Director Ramkumar Mandalam sold 3,217 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $14.68, for a total transaction of $47,225.56. Following the completion of the sale, the director now directly owns 43,187 shares in the company, valued at $633,985.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Ramkumar Mandalam sold 3,217 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $14.68, for a total value of $47,225.56. Following the completion of the sale, the director now owns 43,187 shares in the company, valued at approximately $633,985.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jerrell Shelton sold 3,723 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $16.35, for a total transaction of $60,871.05. Following the completion of the sale, the chief executive officer now owns 636,951 shares of the company’s stock, valued at approximately $10,414,148.85. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 73,940 shares of company stock worth $1,147,538. Corporate insiders own 10.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Conestoga Capital Advisors LLC raised its holdings in shares of Cryoport by 1.0% during the 1st quarter. Conestoga Capital Advisors LLC now owns 71,417 shares of the company’s stock valued at $1,264,000 after purchasing an additional 690 shares in the last quarter. Arizona State Retirement System raised its holdings in shares of Cryoport by 5.4% during the 4th quarter. Arizona State Retirement System now owns 13,665 shares of the company’s stock valued at $212,000 after purchasing an additional 696 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Cryoport by 13.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,462 shares of the company’s stock valued at $157,000 after purchasing an additional 1,395 shares in the last quarter. Natixis Investment Managers International raised its holdings in shares of Cryoport by 61.5% during the 4th quarter. Natixis Investment Managers International now owns 4,536 shares of the company’s stock valued at $70,000 after purchasing an additional 1,727 shares in the last quarter. Finally, Advisors Capital Management LLC grew its stake in Cryoport by 2.5% in the 3rd quarter. Advisors Capital Management LLC now owns 78,993 shares of the company’s stock valued at $1,083,000 after buying an additional 1,947 shares during the last quarter. Institutional investors own 92.90% of the company’s stock.

Cryoport Price Performance

Shares of NASDAQ:CYRX opened at $16.81 on Friday. The firm’s 50 day moving average is $16.90 and its two-hundred day moving average is $15.06. Cryoport has a 52 week low of $9.00 and a 52 week high of $24.17. The firm has a market capitalization of $826.38 million, a P/E ratio of -7.64 and a beta of 1.60. The company has a current ratio of 11.73, a quick ratio of 11.16 and a debt-to-equity ratio of 0.82.

Cryoport (NASDAQ:CYRX) last announced its quarterly earnings results on Tuesday, March 12th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.19). Cryoport had a negative net margin of 42.69% and a negative return on equity of 11.86%. The firm had revenue of $57.26 million during the quarter, compared to analyst estimates of $58.27 million. Analysts anticipate that Cryoport will post -1.31 earnings per share for the current year.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.